Idiopathic infantile hypercalcemia is characterized by hypercalcemia, dehydration, vomiting, and failure to thrive, and it is due to mutations in 24-hydroxylase (CYP24A1). Recently, mutations in sodium-phosphate cotransporter (SLC34A1) expressed in the kidney were discovered as an additional cause of idiopathic infantile hypercalcemia. This report describes a female infant admitted for evaluation of nephrocalcinosis. She presented with hypercalcemia, hypercalciuria, low intact parathyroid hormone level, and high 1,25-dihydroxyvitamin D3 level. Exome sequencing identified novel compound heterozygous mutations in SLC34A1 (c.1337G>A, c.1483C>T). The patient was treated with fluids for hydration, furosemide, a corticosteroid, and restriction of calcium/vitamin D intake. At the age of 7 months, the patient's calcium level was within the normal range, and hypercalciuria waxed and waned. Renal echogenicity improved on the follow-up ultrasonogram, and developmental delay was not noted. In cases of hypercalcemia with subsequent hypercalciuria, DNA analysis for SLC34A1 gene mutations and CYP24A1 gene mutations should be performed. Further studies are required to obtain long-term data on hypercalciuria and nephrocalcinosis.
Introduction
Idiopathic infantile hypercalcemia (IIH) is a rare disease entity of hypercalcemia characterized by failure to thrive, dehydration, vomiting, nephrocalcinosis, and hypercal cemia. 1) In the past, IIH was diagnosed after exclusion of other diseases related to development of hypercalcemia, such as WilliamsBeuren syndrome, hyperparathyroidism, diuretic usage, and excess vitamin D intake. 2) Mutations in CYP24A1, which encodes 24hydroxylase, responsible for degradation of 25hydroxyvitamin D (25OHD) and 1,25dihydroxyvitamin D (1,25OHD), were discovered as a cause of IIH.
3) However, a recent report described mutations in SLC34A1, which encodes the sodiumphosphate cotransporter, resulting in phosphate depletion and inappropriate production of 1,25hydroxyvitamin D with subsequent hypercalcemia. 4) Herein, we describe an infant with IIH caused by a novel mutation in SLC34A1 and provide a literature review.
Case report
A 28dayold Korean female presented with increased renal echogenicity that was detected on prenatal ultrasonography at 28 weeks gestation. She was the second child of unrelated parents. The mother of the neonate was healthy, and the father had a history of nephrolithiasis. The sister of the neonate was 6 years old and healthy. The patient was born at term after an www.e-apem.org uncomplicated pregnancy and normal delivery with a birth weight of 2.95 kg. The infant was exclusively fed breast milk. A vitamin D supplement was not given to the patient or her mother.
Poor feeding, hypotonia, lethargy, and irritability were not noted. Stool frequency was one time per week. At admission, the patient's height and weight were 52.4 cm (25th percentile) and 3.7 kg (15th-25th percentile), respectively. Urine output measured 7.7 mL/kg/day. On physical examination, no dysmorphic facial features of WilliamsBeuren syndrome were found. Subcutaneous necrosis was not found. A renal ultrasonogram revealed bilateral medullary nephrocalcinosis (Fig. 1) . A transthoracic echocardiogram showed 2 atrial septal defects without cardiovascular signs of WilliamsBeuren syndrome.
Results of the laboratory investigations confirmed hypercal cemia and hypophosphatemia. Serum levels of total calcium and pHadjusted ionized calcium were 12.8 mg/dL (normal range, 8.8-10.8 mg/dL) and 3.33 mEq/L (normal range, 2.2-2.5 mEq/L), respectively. The serum level of phosphate was 4.3 mg/dL (normal range for age, 4.8-8.2 mg/dL). The albumin level, which can affect the serum level of total calcium, was within the normal range (4.1 g/dL). Blood urea nitrogen and creatinine levels were 21 mg/dL and 0.35 mg/dL, respectively. Hypercalciuria was noted. The calcium/creatinine ratio of spot urine was 2.81 (normal for age, <0.8), and 24hour urinary calcium excretion was 20.4 mg/kg (normal range, <4 mg/kg). Results of the blood gas analysis revealed no metabolic acidosis that could be related with renal tubular acidosis. The intact parathyroid hormone (PTH) was suppressed to 3.6 pg/mL (normal value, 15.0-65.0 pg/mL), and the PTHrelated protein level was <1.1 pmol/L. The 25OHD level was 13.01 ng/mL (normal range, >20 ng/mL), and the 1,25OHD level was 71.27 pg/mL (normal range, 19.654.3 pg/mL). Serum levels of sodium, potassium, glucose, and magnesium and the complete blood cell count were within normal range.
Under the suspicion of infantile hypercalcemia, we con ducted targeted exome sequencing. The process of targeted exome sequencing consisted of genomic DNA extraction, exome sequencing, filtering, analysis, and Sanger sequencing validation in the patient and her parents. Library preparation and massively parallel sequencing were conducted with the TruSight One sequencing panel (Illumina, San Diego, CA, USA) and NextSeq (Illumina), respectively. Generated reads were aligned to the hg19 human reference sequence. No mutation of CYP24A1 was identified. However, SLC34A1 missense mutations were identified in the compound heterozygous state in the patient (c.1337G>A, c.1483C>T) and were validated by Sanger sequencing (Fig. 2) . Sanger sequencing of the parents Clinical course of the patients is demonstrated in Fig.3 . To treat the patient's hypercalcemia, intravenous hydration with normal saline was started on the second day of hospi talization. Intravenous furosemide was also administered to the patient (1 mg/kg/day) at that time. After 7 days of hospitalization, the patient's serum calcium level decreased to 11 mg/dL, but ionized calcium was still elevated (3.26 mEq/L). For this reason, a corticosteroid (hydrocortisone, 3 mg/kg/day) was administered for 1 week. All medications were stopped at the age of 45 days. Thereafter, the patient was fed lowcalcium, vitamin Dfree formula (Calcilo XD, Abbott Nutrition, Columbus, OH, USA) for 3 months.
Currently, at the age of 7 months, the patient's calcium and phosphate levels are within normal range, and hypercalciuria waxes and wanes. The previously noted renal echogenicity improved on the followup ultrasonogram, and developmental delay was not noted. Limited data on natural history and longterm prognosis of IIH are available. Two siblings (1 boy and 1 girl) with mutations in SLC34A1 resulting in the substitution of histidine for arginine at position 495 were reported recently. The boy presented with hypercalcemia and nephrocalcinosis at 18 months.
5)

Discussion
Calcium and phosphate are important components of bone mineralization and cellular activities, and the serum levels of calcium and phosphate are controlled within narrow limits by the kidney.
6) Schlingmann et al. 3) revealed that mutations in CYP24A1, which encodes 24hydroxylase, the key enzyme for degradation of 25OHD and 1,25OHD, were causative for infantile hypercalcemia.
Recently, mutations in SLC34A1 encoding sodiumphos phate cotransporter 2a (NPT2a) were reported to lead to hypercalcemia, hypercalciuria, hypophosphatemia, and accumulation of 1,25OHD3. NPT2a and NPT2c (encoded by SLC34A3) are expressed in the kidney and reabsorbed as filtered phosphate. 7) Vitamin D, PTH, and fibroblast growth factor 23 (FGF23) are the major control mechanisms of calcium and phosphate. FGF23 is a phosphatonin that restricts renal reabsorption of phosphate through NPT2a. Additionally, FGF23 activates 24hydroxylase and inhibits 1αhydroxylase, resulting in decreased level of 1,25OHD. 4) Patients with mutations in SLC34A1 have decreased ability for renal phosphate reabsorption. The subsequent hypophosphatemia reduces the production of FGF23, resulting in activation of 1αhydroxylase and inhibition of 24hydroxylase. Consequently, patients present with increased level of 1,25OHD that induces hypercalcemia, hypercalciuria, and nephrocalcinosis. 8) Patients with infantile hypercalcemia present with vomi ting, polyuria, dehydration, hypotonia, failure to thrive, and nephrocalcinosis.
3) One study noted that polyuria was induced by disturbance of urine concentration in rats. 9) Nephrocalcinosis was associated with hypercalciuria in another study.
10) The prevalence of nephrocalcinosis in patients with IIH due to mutation in NPT2a has not been identified. In the literature, however, all 18 patients with mutations in SLC34A1 had nephrocalcinosis. 4, 5, 11) Among patients with hypercalcemia and subsequent hypercalciuria, infantile hypercalcemia must be considered.
In the present case, the patient's father had a history of nephrolithiasis. Even a heterozygous mutation carrier presented with nephrolithiasis and renal phosphate leakage. 4, 12) Therefore, patients who are asymptomatic heterozygous carriers should undergo additional evaluations. www.e-apem.org
Treatment of acute hypercalcemia includes rehydration and loop diuretics. Aggressive hydration with normal saline restores intravascular volume and enhances calcium excretion. Furosemide (0.5-1 mg/kg, every 6 hours) promotes calciuresis. 13) Other treatment options include a corticosteroid, calcitonin, and ketoconazole. 14) Ketoconazole inhibits 1αhydroxylase at doses of 3-9 mg/kg. 15) Oral phosphate therapy at a dose of 0.5-1 mmol/kg/day has been documented in a report of a patient who developed hypercalcemia due to mutations in SLC34A1. 4) Long term management of hypercalcemia includes a lowcalcium diet and avoidance of vitamin D. However, calcium and vitamin D restriction can be associated with diseases such as osteoporosis.
Longterm management of nephrocalcinosis includes high fluid intake, potassium citrate, and thiazide. 16) Urinary citrate binds to calcium and forms a soluble compound, resulting in reduction of calcium precipitation. Thiazide increases tubular calcium absorption and decreases renal calcium excretion. Although optimal dosing is not yet established, a daily dose of 0.5-2 mg/kg was effective in the decrement of urine calcium in children. 17) In conclusion, clinicians need to consider testing for muta tions of SLC34A1 in patients with hypercalcemia, hypercalciuria, and nephrocalcinosis. Further studies in similar patients that explore the clinical course, longterm prognosis, and efficacy of a supplement with phosphate are required.
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